Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: The purpose of this study is to evaluate the influence of chronic opioid dependence on postoperative outcomes following primary total ankle arthroplasty (TAA).
Methods: The Nationwide Readmissions Database (NRD) was queried from 2016 to 2020 to identify 29,751 patients undergoing primary elective TAA with patients divided into cohorts based on the presence of preoperative opioid dependence (861 patients; 2.9 %).
Results: The overall cohort was majority male (54.2 %) with mean age of 64.15 (range 17-90) years, and Charlson-Deyo Comorbidity Index score of 0.65 (range 0-12). Preoperative opioid dependence was significantly predictive of increased risk of wound dehiscence (OR=5.365; p < .001), adverse discharge (OR=1.443; p < .001), extended stay greater than 4 days (OR= 1.438; p < .001), and more than a $1000 increase in the total cost of admission (β= 1052.27; p = .027).
Conclusion: Chronic preoperative opioid use was significantly predictive of higher rates of postoperative complications, LOS, and substantially higher cost of admission for TAA.
Level Of Evidence: Level III, Retrospective Cohort Study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.fas.2025.01.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relationship Between State Policies Targeting Unethical Treatment Practices and Opioid-Related Outcomes: An Event Study Analysis.
Subst Use Addctn J
October 2025
Partnered Evidence-based Policy Resource Center, Boston VA Healthcare System, Boston, MA, USA.
Objectives: To estimate the effect of the passage of state laws targeting patient brokering on opioid-related outcomes.
Background: In response to growing awareness of unethical substance use disorder (SUD) treatment practices, several states in the United States have passed laws targeting patient brokering and deceptive marketing. Patient brokering and deceptive marketing laws are intended to reduce the chances individuals with SUD interact with bad actors or suffer from adverse outcomes related to inappropriate SUD treatment, but the effectiveness of these laws is unknown.
Healthcare Expenditures Associated With Implementing an External Facilitation Program to Increase the Prescribing of Medications Used for the Treatment of Opioid Use Disorder Among Veterans.
Subst Use Addctn J
October 2025
Health Economics Resource Center, VA Palo Alto Health Care System, Palo Alto, CA, USA.
Background: To address the opioid use disorder (OUD) public health crisis, the ADvancing Pharmacological Treatments for OUD (ADaPT-OUD) external facilitation randomized trial was conducted in 8 intervention and 27 matched control low-performing Veterans Health Administration (VHA) facilities to increase the prescribing of medications for OUD (MOUD). Facilities were considered low-performers if they were in the bottom quartile of the facility ratio of Veterans with OUD who received MOUD. The objective of this analysis was to evaluate the healthcare expenditures of Veterans with OUD who received care in ADaPT-OUD intervention facilities compared to those receiving care in matched control facilities.
View Article and Find Full Text PDFIdentifying bio-behavioural signatures of persistent opioid use risk in trauma injury patients: a protocol for a prospective cohort study.
BMJ Open
September 2025
Faillace Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, USA.
Introduction: Exposure to prescription opioids following traumatic injury can increase the risk of developing tolerance, persistent opioid use and opioid use disorder. The mechanisms underlying opioid tolerance or dependence are not well understood, and no biomarkers predict risk. Opioid exposure causes epigenetic modifications, including alterations in microRNA (miRNA) expression.
View Article and Find Full Text PDFFentanyl-blocking effects of extended-release naltrexone in humans: Three case reports.
J Opioid Manag
September 2025
Retired Addiction Physician and Psychiatrist, London SE1, United Kingdom. ORCID: https://orcid.org/0000-0002-5035-5833.
Despite the contribution of the µ-agonist fentanyl to the United States's opiate overdose epidemic, no human studies specifically address the ability of extended-release preparations of the opiate antagonist naltrexone (NTX) to block fentanyl's life-threatening µ-agonist-mediated respiratory depression. This paper presents three case histories of clinically necessary opiate challenges in opiate-abusing patients implanted with extended-release NTX (ER-NTX). It also reviews the sparse literature and is the first evidence that antagonist blood levels from ER-NTX preparations can completely block the lethal µ-agonist effects of at least 1,000 mcg of intravenous fentanyl.
View Article and Find Full Text PDFHyperalgesia, allodynia, and eventual overdose: The problems with chronic opioid use.
J Opioid Manag
September 2025
HCA Florida Westside Hospital, Davie, Florida. ORCID: https://orcid.org/0009-0006-5906-983X.
Opioids are known to come with some relatively benign side effects, not including their addictive potential. This review will look at some of the side effects that occur when patients, especially chronic pain patients, take opioids chronically. These side effects include both hyperalgesia and allodynia caused by opioids.
View Article and Find Full Text PDF